(See also Overview of Fungal Infections.)
Chromoblastomycosis is a cutaneous infection affecting normal, immunocompetent people mostly in tropical or subtropical areas; it is characterized by formation of papillomatous nodules that tend to ulcerate.
Chromoblastomycosis is caused by dark brown or black fungi that produce sclerotic bodies in tissue.
Usually, chromoblastomycosis begins on the foot or leg, but other exposed body parts may be infected, especially where the skin is broken. Early small, itchy, enlarging papules may resemble dermatophytosis (ringworm). These papules extend to form dull red or violaceous, sharply demarcated patches with indurated bases. Several weeks or months later, new lesions, projecting 1 to 2 mm above the skin, may appear along paths of lymphatic drainage. Hard, dull red or grayish cauliflower-shaped nodular projections may develop in the center of patches and, if the infection is untreated, gradually extend to cover extremities over the course of many years. Lymphatics may be obstructed, itching may persist, and secondary bacterial superinfections may develop, causing ulcerations and occasionally septicemia.
Late chromoblastomycosis lesions have a characteristic appearance, but early lesions may be mistaken for dermatophytoses.
Fontana-Masson staining for melanin helps confirm the presence of the sclerotic bodies (Medlar bodies), which are pathognomonic. Culture is needed to identify the causative species.
(See also Antifungal Drugs.)
Itraconazole is the most effective drug for chromoblastomycosis, although not all patients respond. Flucytosine is sometimes added to prevent relapse. Amphotericin B is ineffective. Anecdotal reports suggest that posaconazole, voriconazole, or terbinafine may also be effective.
Adjunctive therapies such as cryotherapy are often helpful, although response is slow.
For localized lesions, surgical excision may be curative.
Drugs Mentioned In This Article
|Drug Name||Select Trade|